After two years of the COVID-19 pandemic, the development, clinical and preclinical assessment of pharmacological therapies for this viral infection, continue to be a relevant need. To this end, studies oriented to the evaluation of new potential drugs, as well as, the repurposing of old compounds, will be useful in this scenario.
With the advances in clinical studies in different stages of research, new monotherapies as well as combined approaches, are showing significant effects in reducing mortality, severe disease, the need for mechanical ventilation, hospitalization and even reducing infection. This Research Topic is oriented to spread evidence-based information about different studies providing information of new therapeutic approaches for COVID-19.
All type of articles will be welcome, including Original Research, Systematic Reviews, Reviews and Mini-Reviews, Policy and Practice Reviews, Clinical Trial, Case Reports and Perspective/Opinion articles, among others.
The following themes are welcome:
- Preclinical studies of new compounds for SARS-CoV-2 infection
- Repurposing of old drugs
- Efficacy and effectiveness
- Cost-effectiveness
- Safety
- Modeling
- Pharmacodynamics and pharmacokinetics
- Pharmacoepidemiology and pharmacosurveillance
- Cellular targets
- Outpatient and ambulatory treatment
- Pre and post exposure strategies
- Antivirals
- Monoclonal Antibodies
- Immunomodulators
After two years of the COVID-19 pandemic, the development, clinical and preclinical assessment of pharmacological therapies for this viral infection, continue to be a relevant need. To this end, studies oriented to the evaluation of new potential drugs, as well as, the repurposing of old compounds, will be useful in this scenario.
With the advances in clinical studies in different stages of research, new monotherapies as well as combined approaches, are showing significant effects in reducing mortality, severe disease, the need for mechanical ventilation, hospitalization and even reducing infection. This Research Topic is oriented to spread evidence-based information about different studies providing information of new therapeutic approaches for COVID-19.
All type of articles will be welcome, including Original Research, Systematic Reviews, Reviews and Mini-Reviews, Policy and Practice Reviews, Clinical Trial, Case Reports and Perspective/Opinion articles, among others.
The following themes are welcome:
- Preclinical studies of new compounds for SARS-CoV-2 infection
- Repurposing of old drugs
- Efficacy and effectiveness
- Cost-effectiveness
- Safety
- Modeling
- Pharmacodynamics and pharmacokinetics
- Pharmacoepidemiology and pharmacosurveillance
- Cellular targets
- Outpatient and ambulatory treatment
- Pre and post exposure strategies
- Antivirals
- Monoclonal Antibodies
- Immunomodulators